LLY
Eli Lilly and Company
LLY has the edge over PRCT overall, supported by stronger fundamentals and lower modeled downside.
PRCT
PROCEPT BioRobotics Corporation
PRCT's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
PRCT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
PRCT's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
PRCT PE Valuation
PRCT has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
PRCT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect PRCT's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over PRCT on earnings quality, reporting a profit while its opponent remains loss making.
PRCT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.03 | -$0.51 |
| Q2 2026 | -$1.95 | -$0.41 |
| Q1 2026 | -$1.83 | -$0.14 |
| Q4 2025 | -$1.72 | +$0.03 |
| Q3 2025 | -$1.52 | +$0.43 |
| Q2 2025 | -$1.54 | +$0.52 |
| Q1 2025 | -$1.69 | +$0.43 |
| Q4 2024 | -$1.75 | +$0.49 |
PRCT lost $2.03 per share over the past year, a bigger loss than the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over PRCT on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over PRCT on profitability, with a higher operating margin.
PRCT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $98.3M | +18% |
| Q2 2026 | $94.5M | +19% |
| Q1 2026 | $83.1M | +20% |
| Q4 2025 | $76.4M | +12% |
| Q3 2025 | $83.3M | +43% |
| Q2 2025 | $79.2M | +48% |
| Q1 2025 | $69.2M | +55% |
| Q4 2024 | $68.2M | +57% |
PRCT's revenue has grown year over year every quarter since early 2021: $98M last quarter, up 18% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -28% | 0 points |
| Q2 2026 | -29% | -1 points |
| Q1 2026 | -39% | +0.5 points |
| Q4 2025 | -41% | -12 points |
| Q3 2025 | -28% | +11 points |
| Q2 2025 | -28% | +22 points |
| Q1 2025 | -40% | +22 points |
| Q4 2024 | -29% | +39 points |
PRCT's operating margin was −28% last quarter, about level with the same quarter a year ago, near the top of its range since 2020.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over PRCT on cash generation, producing positive trailing cash flow while its opponent burns cash.
PRCT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.7M | -$149K |
| Q2 2026 | -$22.2M | -$4.4M |
| Q1 2026 | -$41M | -$22.2M |
| Q4 2025 | -$12.2M | +$21.4M |
| Q3 2025 | -$9.5M | +$9.5M |
| Q2 2025 | -$17.8M | -$1.1M |
| Q1 2025 | -$18.8M | +$15.4M |
| Q4 2024 | -$33.6M | -$57K |
PRCT has burned cash in almost every quarter: −$85M over the past year, against −$80M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over PRCT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
PRCT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +259K shares |
| 1 year | +2.9% | +1.6M shares |
| 3 years | +19% | +9M shares |
| 5 years | +39% | +16.1M shares |
PRCT has 57M diluted shares, up 2.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
PRCT Net Leverage
PRCT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
PRCT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.6 | Neutral |
| Stochastic | 60.7 | Neutral |
PRCT's weekly RSI is 55 (neutral) and its Stochastic is 61 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
PRCT PE vs Healthcare Sector
PRCT has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over PRCT on trend strength, trading above more of its moving averages.
PRCT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $19.2 | 22% above |
| 20 week MA | $19.9 | 18% above |
| 50 week MA | $24.5 | 3.8% below |
| 100 week MA | $39.0 | 40% below |
| 200 week MA | $44.3 | 47% below |
PRCT has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 47% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over PRCT on returns for 2026, with the stronger performance.
PRCT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $40.0 | $27.0 | -32% |
| 2022 | $27.0 | $40.9 | +51% |
| 2023 | $40.9 | $41.9 | +2.4% |
| 2024 | $41.9 | $82.0 | +96% |
| 2025 | $82.0 | $32.4 | -60% |
| 2026 YTD | $32.4 | $23.5 | -27% |
PRCT has finished higher in three of the last five years, two of them by more than 50%. It's down 27% so far in 2026.